(Golocdacimab)Biosimilar Reference Antibody-GS40309

货号：GS40309

Golocdacimab (development code MEDI6570) is an investigational, fully human monoclonal antibody being developed for the potential treatment of cardiometabolic diseases, specifically type 2 diabetes (T2D) and its associated complications. It functions as a targeted inhibitor of Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1). By binding with high affinity to LOX-1, golocdacimab blocks its interaction with its primary ligand, oxidized low-density lipoprotein (oxLDL). This blockade aims to inhibit the LOX-1-mediated signaling cascade that contributes to endothelial dysfunction, vascular inflammation, and atherogenesis—pathological processes that are accelerated in type 2 diabetes and drive cardiovascular risk.